Economic evaluation of adding dapagliflozin to standard care in the treatment of chronic kidney disease: a systematic review
Lu Wang, Yinglin Wang, Quan Zhao · 2024
Read Economic evaluation of adding dapagliflozin to standard care in the treatment of chronic kidney disease: a systematic review by Lu Wang, Yinglin Wang, Quan Zhao (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11657770.txt.
Description
Lu Wang, Yinglin Wang, and Quan Zhao weigh the cost worth of a new kidney pill in a 2024 review of health costs. Long kidney ills are a broad health load round the world at this time of care. The pill has shown gains in life cheer for such patients in past trials of its use.
The sweep asks if the pill plus norm care beats norm care in cost per gain for the ill. Five sources yield a score of past cost checks for the pair in the pool. Two hands sift and grade each check by a set rule list for the work.
Catalog record
| CREATOR | Lu Wang, Yinglin Wang, Quan Zhao |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |